Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study
These results support the novel perioperative durvalumab regimen for patients with resectable NSCLC from the AEGEAN study, and no dose adjustment is necessary based on the PopPK and ER analyses.
Authors
- Song Ren (ORCID: https://orcid.org/0000-0001-5046-9008)
- Diansong Zhou (ORCID: https://orcid.org/0000-0002-2673-1069)
- KyoungSoo Lim (ORCID: https://orcid.org/0000-0002-3663-4043)
- Xiaoying Zhao (ORCID: https://orcid.org/0009-0006-3950-8807)
- Allen C. Chen
- Gary J. Doherty (ORCID: https://orcid.org/0000-0002-8158-8111)
- Y Zhang
- Peiming Ma (ORCID: https://orcid.org/0000-0003-0246-3132)
- Nevin L. Zhang (ORCID: https://orcid.org/0000-0002-4662-3217)
- Cathy O’Brien
- Aburough Abegesah
- Jiajia Zhao (ORCID: https://orcid.org/0000-0001-8129-2305)
- Junjie Ding (ORCID: https://orcid.org/0000-0002-6429-3178)
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Oxford (GB)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (France) (FR)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- AstraZeneca (Germany) (DE)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1002/bcp.70287
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca